NCT00206648 (ABOVE) is a Phase 4 clinical trial of Betaferon/Betaseron in Multiple Sclerosis, Relapsing-Remitting, sponsored by Bayer.

Who is sponsoring NCT00206648?

NCT00206648 is sponsored by Bayer.

What drugs are being tested in NCT00206648?

Interventions in NCT00206648: Betaferon/Betaseron, Betaferon/Betaseron.

What condition does NCT00206648 study?

NCT00206648 studies Multiple Sclerosis, Relapsing-Remitting.

Is NCT00206648 still recruiting?

NCT00206648 is currently completed. Last updated 30 December 2014.

Last reviewed 2014-12-30 · How we verify

NCT00206648: ABOVE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized, Rater-blinded, Multicenter, Parallel-group Study Comparing the Efficacy and Safety of Betaseron 250 µg Subcutaneously Every Other Day With Avonex 30 µg Intramuscularly Once Per Week in Relapsing-remitting Multiple Sclerosis Patients Previously Treated With Avonex

Completed Phase 4 Last updated 30 December 2014

What this trial tests

Phase 4 trial testing Betaferon/Betaseron in Multiple Sclerosis, Relapsing-Remitting in 271 participants. Completed in 1 October 2005.

Timeline

1 March 2003

1 October 2005

Quick facts

Lead sponsor	Bayer
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	271
Start date	1 March 2003
Estimated completion	1 October 2005
Sites	53 locations across United States, Canada

Drugs / interventions tested

Betaferon/Betaseron — full drug profile →
Betaferon/Betaseron — full drug profile →

Conditions studied

Multiple Sclerosis, Relapsing-Remitting — all drugs for Multiple Sclerosis, Relapsing-Remitting →

Sponsor

Bayer — full company profile →

Who can join

Adults 18 to 60, any sex, with Multiple Sclerosis, Relapsing-Remitting. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Time to onset of first relapse
Time frame: Time to onset of first relapse

Sponsor's own description

The purpose of this study is to determine the difference in preventing a relapse between Betaseron and Avonex. Patients with RRMS currently treated with Avonex will be randomized into 2 equal-size arms; one arm will continue on the standard dose of Avonex; one arm will be converted to Betaseron standard dose.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.
Tramacere I, Virgili G, Perduca V, Lucenteforte E, et al · · 2023 · cited 10× · PMID 38032059 · DOI 10.1002/14651858.cd012186.pub2

Verify or expand the search:

Other recruiting trials for Multiple Sclerosis, Relapsing-Remitting

Currently open trials in the same condition.

NCT06408259 — Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relap · Phase 3 · recruiting
NCT06569550 — Fatigue Alleviation Through Neuromodulating Therapy in Multiple Sclerosis · NA · recruiting
NCT06389968 — Light Stimulation to Improve Visual Function After Optic Neuritis in Persons with Multiple Sclerosis · NA · recruiting
NCT06345157 — ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients · active not recruiting
NCT06715436 — Multiple Sclerosis and the Effects of Ketogenic Diet Therapy · NA · recruiting

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00206648 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 30 December 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00206648.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing